XALKORI Drug Patent Profile

When do Xalkori patents expire, and what generic alternatives are available?

Xalkori is a drug marketed by Pf Prism Cv and is included in two NDAs. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-six countries.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this compound. Additional details are available on the crizotinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Xalkori

Xalkori was eligible for patent challenges on August 26, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 8, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for XALKORI

International Patents:	105
US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	51
Patent Applications:	6,248
Drug Prices:	Drug price information for XALKORI
What excipients (inactive ingredients) are in XALKORI?	XALKORI excipients list
DailyMed Link:	XALKORI at DailyMed

See drug prices for XALKORI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for XALKORI

NDA:

202570

Dosage:

CAPSULE;ORAL

NDA:

217581

Dosage:

CAPSULE, PELLETS;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for XALKORI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	Phase 2/Phase 3
Bristol-Myers Squibb	Phase 3
Zai Lab (Shanghai) Co., Ltd.	Phase 3

See all XALKORI clinical trials

Pharmacology for XALKORI

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 2B6 Inhibitors Cytochrome P450 3A Inhibitors Organic Cation Transporter 1 Inhibitors Organic Cation Transporter 2 Inhibitors P-Glycoprotein Inhibitors Receptor Tyrosine Kinase Inhibitors

US Patents and Regulatory Information for XALKORI

XALKORI is protected by five US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023		RX	Yes	No			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011		RX	Yes	No			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011		RX	Yes	No			Y	Y
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011		RX	Yes	Yes			Y	Y

Expired US Patents for XALKORI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-002	Sep 7, 2023
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-001	Aug 26, 2011
Pf Prism Cv	XALKORI	crizotinib	CAPSULE;ORAL	202570-002	Aug 26, 2011
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-003	Sep 7, 2023
Pf Prism Cv	XALKORI	crizotinib	CAPSULE, PELLETS;ORAL	217581-001	Sep 7, 2023

EU/EMA Drug Approvals for XALKORI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Xalkori	crizotinib	EMEA/H/C/002489XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to	Authorised	no	no	no	2012-10-23

International Patents for XALKORI

When does loss-of-exclusivity occur for XALKORI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Nicaragua

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering XALKORI around the world.

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	2114	Aminoheteroaryl compounds as protein kinase inhibitors
Australia	2004215428	Aminoheteroaryl compounds as protein kinase inhibitors
Brazil	PI0407827	compostos de aminoeteroarila como inibidores de proteìna cinase
Canada	2517256	COMPOSES D'AMINOHETEROARYLE UTILISES EN TANT QU'INHIBITEURS DE PROTEINE KINASE (AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS)
China	103265477	Aminoheteroaryl compounds as protein kinase inhibitors
China	1777427	Aminoheteroaryl compounds as protein kinase inhibitors
Costa Rica	7961	COMPUESTOS DE AMINOHETEROARILO COMO INHIBIDORES DE LAS PROTEINQUINASAS

Supplementary Protection Certificates for XALKORI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1786785	PA2013005	Lithuania		PRODUCT NAME: CRIZOTINIBUM; REGISTRATION NO/DATE: EU/1/12/793/001 - EU/1/12/793/004 20121023
1786785	CA 2013 00009	Denmark
1786785	92155	Luxembourg		PRODUCT NAME: CRIZOTINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE
1786785	C300587	Netherlands		PRODUCT NAME: CRIZOTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/12/793/001-004 20121023
1786785	C20130007 00075	Estonia		PRODUCT NAME: KRISOTINIIB;REG NO/DATE: K(2012)7617 LOPLIK 23.10.2012
1786785	2013/009	Ireland		PRODUCT NAME: PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED: CRIZOTINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/12/793/001 EU/1/12/793/004 20121023
1786785	13C0015	France		PRODUCT NAME: CRIZOTINIB ET SES SELS, HYDRATES ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/793/001 20121026

XALKORI (crizotinib) market dynamics and financial trajectory: sales trends, exclusivity, and patent-driven competitive pressure

Last updated: June 23, 2026

Executive summary: XALKORI (crizotinib) remains a long-tail oncology product with shrinking market share as next-generation ALK inhibitors (notably alectinib, brigatinib, and lorlatinib) displaced it in first-line and broader-line ALK+ non-small cell lung cancer. Financially, the trajectory is dominated by (1) declining demand since peak penetration, (2) erosion from guideline- and payer-driven preference shifts toward newer ALK therapies, and (3) patent-expiration and generic-entry risk that accelerated competitive pressure for crizotinib cohorts over time. The commercial outlook is tied less to incremental label expansion and more to remaining exclusivity, settlement dynamics, and the residual value of historical prescribing patterns.

---

How has XALKORI (crizotinib) sales trended over time and what drives market dynamics?

Short answer: XALKORI sales have followed a standard first-generation targeted-therapy curve: early growth on ALK biomarker uptake and differentiated efficacy signals, then sustained decline as more effective ALK inhibitors moved into earlier lines and expanded guideline dominance.

Primary demand drivers

• ALK biomarker adoption: Uptake of ALK testing increases addressable patient volume, but does not prevent revenue erosion once treatment algorithms shift.
• Line-of-therapy migration: Once clinical evidence and guideline updates favored second-generation ALK inhibitors (better CNS penetration and improved durability), prescribing shifted away from crizotinib.
• Safety and CNS control: Newer ALK inhibitors improved overall tolerability profiles and intracranial disease control, which matters for payer coverage decisions and treatment sequencing.
• Wholesale/channel mechanics: Oncology branded drugs can hold revenue longer through inventory cycles and formulary inertia, but ultimately track clinical guideline adoption.

Key market-structure factors

• Payer formularies: Health plans increasingly require step therapy or prior authorization for older ALK agents once lower-cost competitors or preferred alternatives are available.
• Uptake of newer ALK inhibitors: Alectinib, brigatinib, and lorlatinib reduced crizotinib’s addressable share by winning dominant positions across multiple lines.
• Residual opportunity in later lines: Crizotinib can persist for patients who have already received other therapies, but that cohort shrinks with time.

Financial trajectory indicators to watch

• Net sales trend: expected downward slope with periodic plateau during payer exceptions.
• Mix shift: fewer new starts, more continuation patients early in displacement waves.
• Country and contract segmentation: revenue durability differs materially by market.

(Note: This analysis is structured for decision-use, but it does not include audited revenue figures because no company financial table or sales dataset is cited in the provided input.)

---

What exclusivity and patent estate factors affect XALKORI’s commercial lifespan?

Short answer: XALKORI’s market dynamics are largely governed by patent expiry and follow-on IP (formulations, dosing regimens, and method-of-use) rather than by new clinical differentiation.

How exclusivity typically breaks for an oral small molecule

• First wave: Composition-of-matter and early method claims underpin initial exclusivity.
• Second wave: Later-expiring patents can cover:
  • crystalline forms or specific salt/polymorph strategies,
  • controlled-release or formulation approaches,
  • dosing regimens tied to clinical endpoints,
  • expanded or specific biomarker-selected indications.

Why “follow-on” patents matter commercially

When first-wave patents expire, generic entry timing often depends on whether remaining claims are strong enough to deter Paragraph IV challenges or to support injunction leverage in settlement.

What to map in an IP-driven timeline

• Patent filing-to-expiration schedule for primary and secondary claims.
• Filing and status of any ANDA filings, Paragraph IV notices, and related litigation.
• Scope of settlements that define “authorized generic” or market carve-outs.

---

When does XALKORI lose exclusivity and what generic entry risks exist?

Short answer: Generic entry risk rises in windows where the core composition and the most commercially relevant downstream claims expire or weaken under litigation.

What “generic entry risk” means for market outcomes

• Switch timing: Even if a patent expires, market switching depends on:
  • FDA approval timing,
  • launch readiness (CMC, supply),
  • payer contracting and rebate structures.
• Settlement-driven delay: Many oncology small molecules do not face immediate entry even after expiration if disputes settle with agreed launch dates.

Common risk pathways

• ANDA with Paragraph IV: challenges listed Orange Book patents.
• Design-around: generics may attempt to avoid a method-of-use claim by changing labeling or dosing.
• Authorized generics: branded sponsors may license a generic to control launch sequencing and price compression.

---

How many patents cover crizotinib and what categories dominate (formulation, method-of-use, composition)?

Short answer: Crizotinib patent estates generally include composition claims plus follow-on layers for formulation and method-of-use. Commercial relevance is highest for claims that align to:

• oral dosing regimens,
• safety and exposure targets,
• administration formats and formulation stability,
• ALK+ NSCLC diagnostic or treatment selection language.

Patent estate categories to classify (for crizotinib)

• Composition-of-matter (core active ingredient claims).
• Formulation (tablet/capsule composition, coatings, stability, particle size).
• Method-of-use (treatment of ALK+ cancers, line-of-therapy specifications, dosing strategies).
• Manufacturing methods (less common as launch determinants but relevant to injunction leverage).

---

What patent litigation affects XALKORI, including Paragraph IV challenges and settlements?

Short answer: Patent litigation is typically the main determinant of generic launch timing for legacy small-molecule oncology products after core exclusivity weakens.

Litigation signals that move market share

• Presence of multiple litigated Orange Book patents: increases settlement complexity.
• Claim scope overlap: if generics challenge high-value composition/formulation claims, risk accelerates.
• Court outcomes: final judgments or venue decisions can trigger negotiated launch schedules.

Settlement patterns that matter

• Launch date carve-out: agreed “at-risk” end date for branded.
• Geographic restriction: settlements may cover certain territories and leave others exposed.
• Authorized generic: can stabilize revenues while still capturing some cost reduction.

(No specific case captions or docket-linked dates are included here because there is no provided dataset of litigation events.)

---

What is the FDA regulatory status of XALKORI (pathway, approvals, and label scope) and how does it affect commercial performance?

Short answer: XALKORI is an FDA-approved oral targeted therapy for ALK-positive NSCLC. The label scope and sequencing into treatment algorithms affect uptake more than minor regulatory changes.

Regulatory and commercial linkage

• New indication approvals typically boost incremental revenue only if they create a meaningful new line-of-therapy position.
• Label restrictions can limit use in specific settings when newer competitors gain preference.
• Postmarketing safety updates can indirectly shift prescribing patterns and payer comfort.

---

How does XALKORI compare with competing ALK inhibitors (alectinib, brigatinib, lorlatinib) on market positioning and revenue exposure?

Short answer: XALKORI’s competitive disadvantage is clinical sequencing. Next-generation ALK inhibitors are favored for efficacy durability and CNS outcomes, translating into faster share loss and less new patient initiation.

Commercial comparison framing

• XALKORI: first-generation ALK inhibitor; used more in later-line cohorts as newer agents dominate.
• Alectinib/brigatinib/lorlatinib: second- and third-generation ALK inhibition with stronger CNS penetration; widely positioned as preferred first-line options.

Revenue exposure implications

• As first-line preference moves away from crizotinib, revenue becomes:
  • more dependent on continuation patients and restricted prescribing,
  • more exposed to payer tightening and discounting,
  • less insulated against generic erosion if exclusivity expires.

---

What formulations are protected and do delivery or dosing innovations extend revenue?

Short answer: For oral small molecules like crizotinib, formulation patents can extend enforcement leverage after composition expiry, but they rarely reverse market displacement from superior competitors.

Where formulation protection tends to help

• Delaying generic “drop-in” substitutions that trigger automatic pharmacy switching.
• Supporting injunction theories based on specific manufacturing or physical characteristics.

Where formulation protection tends to fail commercially

• If payers switch to preferred ALK agents, patient demand declines faster than IP enforcement can preserve volume.
• If generics enter with therapeutically equivalent products that avoid claim scope, the branded market shrinks regardless.

---

Which markets drive residual XALKORI revenue and where is competitive pressure highest?

Short answer: Residual revenue typically concentrates in markets with:

• slower guideline adoption,
• more restrictive reimbursement policies that slow switching,
• delayed generic entry due to patent enforcement or settlement.

Competitive pressure tends to be highest where:

• newer ALK inhibitors are already preferred and contracted,
• generic substitution is faster after claim cliffs,
• payer policies are more aggressive on cost.

(No country breakdown is included because sales-by-country and IP-by-country data are not provided.)

---

What generic launch scenarios are most plausible for crizotinib and what do they imply for pricing?

Short answer: Most plausible scenarios are either (1) delayed entry via litigation settlement, or (2) launch immediately after high-value patent expiration windows. Either scenario drives significant price compression.

Scenario mechanics

• Delayed launch: branded maintains higher net pricing longer, but share loss to newer ALK inhibitors continues.
• Immediate launch post-expiry: generic price compression reduces branded net sales quickly, with payer-driven switching within contracting cycles.

Downstream effect

• Net revenue declines accelerate when generic entry coincides with reduced new patient starts due to newer ALK inhibitor dominance.

---

Key takeaways

• XALKORI’s financial trajectory is dominated by sequence displacement by next-generation ALK inhibitors and time-to-entry driven by patent estate and litigation outcomes.
• Revenue persistence, when it occurs, comes from continuation patients, payer friction, and settlement-driven launch timing, not from renewed clinical differentiation.
• The most material commercial inflection points are patent cliff windows and the extent of follow-on IP enforceability, because those determine the speed of generic entry and price compression.
• Market share erosion persists even when exclusivity holds because guideline and formulary preference favor newer ALK inhibitors.

---

FAQs

1) Does XALKORI still have meaningful use in current ALK+ NSCLC treatment guidelines?

It can remain used in later lines in practice, but guideline preference and payer contracting increasingly favor newer ALK inhibitors for initial treatment positions, limiting long-term growth and accelerating share decline.

2) What factors determine whether generic crizotinib launches “at risk” or after settlement?

Strength and breadth of litigated Orange Book patents, likelihood of injunction, and settlement leverage tied to commercial importance of specific claims drive whether entry happens after agreed timelines.

3) How do formulation patents change generic substitution for oral oncology small molecules?

Formulation and manufacturing-related claims can delay or deter launches if generics cannot design around without crossing claim scope, but they typically cannot reverse clinical displacement by preferred therapies.

4) Do payer step-therapy and prior authorization impact XALKORI net sales more than label language?

Yes. Utilization management decisions often determine real-world prescribing faster than incremental label updates, especially when preferred alternatives exist.

5) What is the biggest commercial driver of XALKORI revenue over the next few years?

Patent-driven competitive entry timing and the remaining size of continuation cohorts after displacement by second- and third-generation ALK inhibitors.

---

References

1. FDA. Orange Book database. (Accessed via FDA Drugs@FDA / Orange Book).
2. FDA. Drugs@FDA: XALKORI (crizotinib).
3. Bloomberg Intelligence and/or company investor materials. (Not cited because no financial table or document was provided in the input.)